355 results on '"Arend, Rebecca C."'
Search Results
2. Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine
3. Association of allostatic load with overall survival in epithelial ovarian cancer
4. A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment
5. Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients
6. Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years
7. Proteogenomic insights suggest druggable pathways in endometrial carcinoma
8. High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile
9. Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.
10. Five-Year Relative Survival Rates of Women Diagnosed with Uterine Cancer by County-Level Socioeconomic Status Overall and across Histology and Race/Ethnicity.
11. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
12. Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research
13. Therapeutic Potential of a Plant-Based Diet in Reducing Pain and Tumor Growth
14. Abstract A017: An analysis of 13 independently performed assays to measure homologous recombination deficiency using 90 freshly extracted high grade serous ovarian tumors: findings from the friends of cancer research hrd harmonization project
15. Abstract A021: Pilot study of daily exemestane in patients with Endometrial Intraepithelial Neoplasia (EIN) or grade 1 endometrial cancer
16. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer
17. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II
18. TGFβ signaling networks in ovarian cancer progression and plasticity
19. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
20. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
21. Dedicated Research Navigators: A Tool to Eradicate Disparities in Clinical Trial Enrollment?
22. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer
23. Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
24. Checkpoint inhibitors in ovarian cancer: A review of preclinical data
25. Overcoming immune suppression with epigenetic modification in ovarian cancer
26. Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
27. Proteogenomic insights suggest druggable pathways in endometrial carcinoma
28. Heparan sulfate modifications of betaglycan promote TIMP3-dependent ectodomain shedding to fine-tune TGF-β signaling.
29. Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey
30. Endometrial cancer: Molecular markers and management of advanced stage disease
31. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
32. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review
33. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models
34. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
35. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
36. Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review
37. Supplementary Data from Circulating Tregs Accumulate in Omental Tumors and Acquire Adipose-Resident Features
38. Data from Circulating Tregs Accumulate in Omental Tumors and Acquire Adipose-Resident Features
39. Supplementary Table 1 from Effect of Niclosamide on Basal-like Breast Cancers
40. Data from Effect of Niclosamide on Basal-like Breast Cancers
41. Supplementary Figure 1 from Effect of Niclosamide on Basal-like Breast Cancers
42. Supplementary Figure 3 from Effect of Niclosamide on Basal-like Breast Cancers
43. Supplementary Figure 5 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
44. Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
45. Data from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
46. Supplementary Table 2 from Effect of Niclosamide on Basal-like Breast Cancers
47. Supplementary Figure 5 from Effect of Niclosamide on Basal-like Breast Cancers
48. Supplementary Figure 2 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
49. Supplementary Figure 4 from Effect of Niclosamide on Basal-like Breast Cancers
50. Supplementary Figure 1 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.